Cytokines as Key Players in the Pathophysiology of Preeclampsia

Raj Raghupathy

Department of Microbiology, Faculty of Medicine, Health Sciences Centre, Kuwait University, Safat, Kuwait

Key Words
Preeclampsia · Cytokines · Pregnancy · T helper 1 · T helper 2 · Inflammation

Abstract
Preeclampsia (PE) is an important, common, and dangerous complication of pregnancy; it causes maternal and perinatal illness and is responsible for a high proportion of maternal and infant deaths. PE is associated with increased blood pressure and proteinuria, with a whole host of other potentially serious complications in the mother and fetus. The maternal syndrome in PE is primarily that of generalized dysfunction of the maternal endothelium, and this generalized endothelial dysfunction appears to be part of an exaggerated systemic inflammatory response that involves maternal leukocytes and proinflammatory cytokines. This review examines evidence that points to a significant role for the maternal immune system; inadequate trophoblast invasion of spiral arteries initiates ischemia and hypoxia in the placenta, resulting in an increased release of proinflammatory cytokines in the placenta. Placental ischemia and hypoxia also cause the enhanced release of trophoblast microparticles into the maternal circulation which stimulates increased induction of proinflammatory cytokines and the activation of maternal endothelial cells. This activation results in a systemic, diffuse endothelial cell dysfunction which is the fundamental pathophysiological feature of this syndrome. Recent evidence also supports important roles for proinflammatory cytokines in hypertension, proteinuria, and edema which are characteristic features of PE.

Introduction

The process of pregnancy is besieged by many potential challenges, of which one of the most common is preeclampsia (PE), a multisystem disorder unique to pregnancy associated with elevated blood pressure (BP) and proteinuria typically presenting after 20 weeks of gestation. Gestational hypertension is the presence of new hypertension (usually systolic BP >140 mm Hg and/or diastolic BP >90 mm Hg) occurring in the second half of pregnancy, while PE is the combination of gestational hypertension with new proteinuria [1].

Worldwide, PE is the most common of the various hypertensive disorders of pregnancy, affecting an estimated 2–10% of pregnant women [2, 3]. More than 4 million women across the world develop this disorder every year [4], and an estimated 50,000–76,000 women and 500,000 infants die of this condition every year [3]. In fact, PE is a principal cause of fetal morbidity and mortality and causes 15–20% of maternal deaths worldwide [5].
Symptoms of PE may include edema of the hands and face/eyes and weight gain; severe PE may present with headaches, abdominal pain, agitation, decreased urine output, nausea, vomiting, and vision changes. PE is perhaps the most dangerous complication of pregnancy because it has the greatest effect on maternal and infant outcomes [3, 6, 7] and is the chief cause of protracted antenatal hospital stay, induced preterm delivery, and slow growth of infants. Adverse conditions associated with PE include maternal multisystem complications such as oliguria, thrombocytopenia, pulmonary edema, right upper quadrant pain, elevated liver enzymes, and unfavorable placental/fetal outcomes such as abruptio placentae, intrauterine growth restriction, oligohydramnios, and absent or reversed umbilical artery diastolic flow [7]. Thus, a wide range of potentially serious fetal and maternal conditions are associated with PE.

What induces PE? How is the pathophysiology of PE mediated? What are the mechanisms underlying PE-associated hypertension, proteinuria, and edema? These questions have plagued researchers and clinicians alike, even though PE has been known for a long time now. In 1916, Zweifel [8] described PE as ‘a disease of theories’ presumably because of the innumerable theories and speculations put forth to explain the etiopathogenesis of what has been described as ‘a complex, elusive and unpredictable disease’ [9, 10]. Indeed, Saito [11] describes PE as involving a ‘chaos of theories’. However, intensive research in the last decade has contributed to a better understanding of the pathogenesis of PE. Most investigators now agree that the basic cause of the diverse maternal symptoms of PE is a generalized dysfunction of maternal endothelium [12] which seems to be a part of a generalized systemic inflammatory response that involves maternal leukocytes.

**Pathogenesis of PE**

The sequence of events in PE is proposed to occur in two stages: a ‘placental’ stage (or stage 1) and a ‘peripheral’ stage (or stage 2) [12]. During stage 1, inadequate development of maternal spiral arteries results in a deficient maternal blood supply to the placenta, bringing about placental ischemia and hypoxia; this appears to be followed by stage 2, consisting of the classic manifestations of widespread endothelial dysfunction, hypertension, proteinuria, and edema (fig. 1).

The fetus depends on the blood supply from the mother flowing into placental blood spaces via maternal spiral
arteries which are the terminal branches of radial arteries that run from the uterus through the decidua. Spiral arteries, under normal circumstances, are invaded by placental cytотrophoblast cells which replace the endothelium of these arteries and remodel the vascular wall, causing the blood vessels to dilate [13] and thus better accommodate the increased blood supply needed by the fetus and placenta [14]. On the other hand, in PE, trophoblast invasion of spiral arteries is insufficient, resulting in narrower blood vessels [15] which are unable to transport adequate blood to the placenta which then becomes increasingly ischemic in the second half of the pregnancy [reviewed in 16]. Thus, shallow trophoblast invasion [17, 18] and improper remodeling of the spiral arteries [19, 20] are believed to result in abnormal prolongation of hypoxia. In addition to placental ischemia, acute atherosis of spiral arteries adds a further complication. Spiral arteries with poor trophoblast invasion and remodeling also show signs of acute atherosis which includes disruption of the endothelium, fibrinoid necrosis, and leukocytic infiltration, leading to partial or complete blockage of the arteries [21]. This secondary complication aggravates the problem of poor blood-conducting ability, resulting in hypoxia of the placenta which in turn causes several gross and histological changes such as infarcts, proliferation of the cytotrophoblast, and outgrowth lesions of the syncytiotrophoblast [22]. Perhaps the most relevant outcome of this damage to the placenta is the shedding of trophoblast cells and trophoblast microparticles into the maternal circulation which can be viewed as the beginning of stage 2 of PE [23].

Stage 2 of this disease was first described by Redman and colleagues [24] to be the result of diffuse maternal endothelial dysfunction manifested as endotheliosis of renal glomerulae, increased levels of components of the endothelial extracellular matrix, raised plasma levels of fibronectin and von Willebrand factor, increased vascular permeability, enhanced vascular resistance, and platelet aggregation. Furthermore, this generalized endothelial dysfunction can be attributed to trophoblast microparticles originating from the ischemic placenta [23, 24].

Microparticles are present in blood circulation even under normal physiological conditions and can induce cell signaling leading to processes like invasion, angiogenesis, and apoptosis; moreover, microparticles are also involved in thrombosis, inflammation, and vascular dysfunction [25]. Sargent et al. [24] demonstrated the presence of subcellular trophoblast microparticles [termed syncytiotrophoblast microparticles (STBM)] in the plasma of normal pregnant women; levels of STBM were shown to be significantly higher in PE [24, 26, 27]. This led to the hypothesis that STBM is shed into the circulation of PE patients in higher amounts than in normal pregnancies due to oxidative stress brought about by a poor blood supply and hypoxia [27]. STBM are made up of products of trophoblast apoptosis [28] and are reported to inhibit the proliferation of endothelial cells in culture and disrupt the continuity of established endothelial cell monolayers [29]. STBM preparations from PE placentas are qualitatively not different from STBM preparations from normal placentas; their ability to induce endothelial dysfunction is proposed to be due to higher levels in PE [23, 26, 27]. More interestingly, these microparticles provoke endothelial cells to release proinflammatory factors [30, 31] and induce maternal leukocytes and endothelial cells to produce proinflammatory cytokines [12, 32]; this has relevance for the induction of an inflammatory state, which is the focus of this review. In fact, the generalized an excessive maternal inflammatory reaction seen in PE appears to be associated with an increased release of these microparticles [32]. Also released from the placenta in PE are antiangiogenic factors that may act on the endothelia of organs such as the kidney, liver, and brain, resulting in the production, by damaged endothelial cells, of proinflammatory cytokines [reviewed in 16].

**PE: An Immune-Mediated Disease?**

The placenta has the rather challenging task of maintaining a very delicate balance between allowing trophoblast invasion of spiral arteries to take place on the one hand and preventing uncontrolled invasion on the other. Maternal immune cells appear to serve as immunological policemen, thwarting an overly robust trophoblast invasion; at the same time, an exaggerated immune response may restrain this to the extent that it results in insufficient invasion of the arteries and consequently poor vascular remodeling, constricted blood flow, and hypoxia. A role for the immune system has also been shown for the placental damage seen in PE; increased levels of some complement components [33] and higher levels of IgG are found in preeclamptic placentas compared to placentas from normotensive pregnancies [34].

A role for immunologic effectors is more evident in stage 2 of PE, leading up to widespread endothelial damage. Neutrophils are abnormally activated in PE [35] and this activation has been attributed to immune mechanisms, e.g. inflammatory cytokines produced by T cells.
Activated neutrophils could cause vascular damage and interact with platelets and coagulation systems. Clark et al. [35] suggest that the activation of neutrophils, and endothelial cells and platelet/coagulation activate one another, bringing about a vicious cycle of mutual activation. In addition to neutrophils, other immune effectors that appear to play critical roles are cytokines, which are perhaps the most important initiators and mediators of inflammation and endothelial dysfunction; thus, a great deal of attention has been focused on cytokines produced both by the placenta and by leukocytes in the periphery.

Pregnancy, PE, and Inflammation

Pregnancy has been described as a state of ‘mild, controlled inflammation’ [36], while PE appears to be a state of an exaggerated inflammatory response [37, 38]. Both normal and preeclamptic pregnancies show an increased inflammatory response with increasing gestational age [39]. It is suggested that a mild inflammatory response in a normal, successful pregnancy is actually beneficial to pregnancy [40], and that when this inflammatory response becomes amplified it results in the development of PE. Inflammation is necessary during pregnancy, but at the same time needs to be tightly controlled to prevent excessive inflammation, and is probably achieved by reducing the production of proinflammatory cytokines and/or increasing the production of anti-inflammatory cytokines [41, 42]. The abnormal inflammatory response seen in PE is believed to be caused by the higher levels of STBM shed into maternal blood [28–31, 43] which are suggested to cause endothelial dysfunction primarily via the induction of proinflammatory cytokines [12, 23, 24, 27, 36]. Many of the symptoms of PE can be attributed to an inappropriate or exaggerated activation of maternal inflammatory responses. In addition to the activation of neutrophils and monocytes, PE is associated with enhanced production of phospholipase A2, an important mediator of inflammatory reactions [44], increased expression of cell-surface markers of leukocyte activation, C-reactive protein [45], activin A [46], and several inflammatory cytokines. A recent large case-control study showed an association between PE and SEPS1, an inflammatory response gene which is proposed to be responsible for the elevated levels of proinflammatory cytokines and other mediators of inflammation observed in PE [47]. Austgulen et al. [48] showed that levels of the soluble adhesion molecules ICAM-1, VCAM-1, and E-selectin are increased in preeclamptic pregnancies, while levels of these markers and mediators of inflammation in normal pregnancies are significantly lower and similar to those in nonpregnant women.

Toll-like receptors (TLRs) also appear to contribute to the induction of PE [49]. TLRs are part of the innate immune system, and these cell surface receptors recognize evolutionarily conserved pattern-recognition molecular patterns on pathogens. Stimulation of TLRs on monocyte surfaces elicits the production of several cytokines. Interestingly, a recent study showed that the stimulation of TLR4 using low doses of lipopolysaccharide brings about a PE-like syndrome in pregnant rats [49]; indeed, the expression of TLR4 has been shown to be elevated in interstitial trophoblast cells of preeclamptic placentas [50].

Cytokines and PE

Substantial evidence has accrued over the years supporting roles for cytokines in the pathogenesis of PE at the early placental stage and in the later systemic stage as well. Cytokines play critical, essential roles in signaling between cells of the immune system, with a prolific range of regulatory activities including the recruitment, activation, stimulation, killing, and suppression of immune and nonimmune cells. Interestingly, research in the last two decades has shown that cytokines are also involved in several events in pregnancy such as ovulation, implantation, placentation, and parturition [51]. Cytokines like granulocyte-macrophage colony-stimulating factor (GM-CSF), colony-stimulating factor-1, IL-3 [52], and IL-10 [53] contribute to the success of pregnancy, while cytokines such as TNF-α and IFN-γ have been shown to have harmful effects on pregnancy [54, 55]. IL-2, TNF-α, and IFN-γ are characteristic of Th helper 1 (Th1)-type immunity and induce several cell-mediated cytotoxic and inflammatory reactions. Th2-type cells, on the other hand, secrete the Th2 cytokines IL-4, IL-5, IL-6, and IL-10 and are associated with help for humoral immunity [56, 57]. Th2-type immunity is associated with a normal pregnancy, whereas a strong Th1 reactivity is associated with pregnancy complications such as recurrent spontaneous miscarriage [58, 59], preterm delivery [60, 61], and premature rupture of fetal membranes [62]. In addition to being classified as Th1 and Th2 cytokines, cytokines can also be classified as pro- and anti-inflammatory. Cytokines such as IL-1, IL-2, IL-8, TNF-α, and IFN-γ are proinflammatory, and increased levels of such proinflammatory cytokines are associated with pregnancy complications such as preterm delivery [63] and intrauterine growth retardation [64].
Cytokines in the Placenta

Cytokines are produced by cells of normal placentas and by leukocytes infiltrating the placenta, and receptors for cytokines are also expressed in the placenta; thus, both sources and targets of cytokines are present in the placenta [51, 65, 66]. Proinflammatory cytokines are produced by placental trophoblasts and also by macrophages and stromal cells of the placenta [67–69]. The anti-inflammatory cytokines IL-4 and IL-10 are also secreted by placental tissues [70]. Cytokines have been shown to play beneficial roles in several normal physiologic processes in the placenta; these include trophoblast invasion and differentiation and placental proliferation and angiogenesis [51, 71, 72].

Widespread upregulation of cytokines in preeclamptic placentas, including proinflammatory cytokines like TNF-α and their receptors, have been shown in DNA microarray studies [73]. The expression and secretion of TNF-α [74–76] and IL-1 [77–79] are elevated in the placentas of preeclamptic women. Hypoxia-reoxygenation due to intermittent perfusion of the placenta has been shown to induce the production of TNF-α and IL-1 [75, 80–82]; Benyo and colleagues [83, 84] demonstrated increased production of the proinflammatory cytokines TNF-α and IL-1 by the normal human placenta under conditions of low oxygen tension. Considering that placental hypoxia occurs in PE, this could well explain the elevated production of these two cytokines. High local production of TNF-α may have significant effects, including increased trophoblastic apoptosis resulting in enhanced syncytial shedding and impaired placental function [85].

Elevated levels of other proinflammatory cytokines, i.e. IL-2 [78] and IL-18 [86], have also been shown in preeclamptic placentas. IL-18 is a proinflammatory cytokine which, in the presence of IL-12, tips the balance of immune reactivity towards a Th1 phenotype. High levels of IL-18 along with high levels of IL-12 [87] in PE are proposed to cause Th1 dominance [88]. Lockwood et al. [89] demonstrated higher levels of IL-6 mRNA and protein in leukocyte-free decidual cells from subjects with PE. Human endometrial endothelial cells have been recently shown to be capable of phagocytosing apoptotic trophoblasts and then secreting the proinflammatory cytokine IL-6 [90]; this might be one of the mechanisms that contribute to the inflammatory response seen in preeclamptic placentas. Increased production of IFN-γ, a Th1 proinflammatory cytokine, has been found in decidual lymphocytes [91] and choriodecidual cells of placentas [92] from preeclamptic pregnancies.

While PE is associated with increased levels of proinflammatory cytokines, it is also associated with decreased placental production of the anti-inflammatory cytokine IL-10 [93–95]. Considering that IL-10 is a strong suppressor of proinflammatory cytokines such as IFN-γ and TNF-α, it is suggested that the placenta responds to hypoxia in PE with insufficient IL-10 production, leading to increased or uncontrolled production of pro-inflammatory cytokines [66]. Furthermore, IL-10 has anti-apoptotic and anti-inflammatory capabilities, and it is therefore quite likely that the decreased IL-10 in the placenta is at least partly responsible for the increased apoptosis of the trophoblast seen in PE [96–98]. While apoptosis is actually necessary for normal placentation, excessive apoptosis or inadequate clearance of apoptotic debris may lead to increased production of proinflammatory cytokines by macrophages [99]. In addition to proinflammatory cytokines, decidua from a murine model of PE display higher levels of GM-CSF as well as increased numbers of both macrophages and dendritic cells when compared to control animals [100]. Furthermore, TNF-α and IL-1 induce increased production of GM-CSF by cultured decidual cells, leading to the suggestion of important roles for GM-CSF in inducing the activation of macrophages and dendritic cells in PE.

Cytokines in the Periphery

Levels of proinflammatory cytokines are increased in the blood and in blood leukocytes in PE. Elevated concentrations of TNF-α have been observed in the blood of women with PE [101–105]. The placenta may not be the major contributor to the high TNF-α levels seen in peripheral blood [84], and in fact peripheral leukocytes, which are in any case in an activated state in PE [106] may contribute significantly to the TNF-α levels in peripheral blood [107]. Levels of soluble TNF-α receptor, a more reliable marker for TNF activity, are also increased in PE as compared to normal pregnancies [108]. Support for a cause-and-effect association between TNF-α and PE comes from Sibai et al. [109] who showed that serum levels of TNF-R2 receptor are indeed elevated prior to overt PE, suggesting a pathogenetic role for these proinflammatory cytokines.

Similarly, enhanced plasma levels of IL-1 [77], IL-2 [110], IL-6 [83, 101, 111, 112], IL-8, and IL-18 [86] have been reported in preeclamptic women. Elevations of IL-6 and IL-8 have also been shown in the amniotic fluid of preeclamptic patients [113]; in fact, elevated levels of IL-6 have been shown to be associated with the onset of PE.
A recent study using a multiplex suspension array technique compared levels of cytokines, chemokines, and adhesion molecules in normotensive pregnancies versus preeclamptic pregnancies [114]. Serum from women with PE had increased Th1/Th2 cytokine ratios as well as increased levels of the cytokines IL-6 and TNF-α, the chemokines IL-8, IP-10, and MCP-1, and the adhesion molecules ICAM-1 and VCAM-1, supporting the existence of a systemic proinflammatory condition in PE.

In contrast to the generally increased levels of proinflammatory cytokines, the blood levels of some anti-inflammatory cytokines such as IL-4 [92, 115] and IL-10 [95] are reduced in patients with PE. The production of cytokines by peripheral blood mononuclear cells (PBMC) has been investigated in several studies. Maternal PBMC produce higher levels of the proinflammatory cytokines TNF-α [116], IFN-γ [116–118], IL-2 [104, 119], IL-1 [120], IL-6 [120], and IL-8 [105, 111, 120]. On the other hand, reduced production of IL-10 [111, 117, 118, 121] and IL-5 by PBMC from patients with PE [111] has been reported.

We conducted a study designed to ascertain whether a Th1-biased cytokine profile exists in women with PE as compared to normal pregnant women. We found that significantly higher levels of the proinflammatory cytokines IFN-γ and TNF-α were produced by women with PE versus normal pregnant women, who on the contrary showed significantly greater production of the Th2 cytokines IL-4, IL-5, and IL-10. A comparison of the ratios of Th2 to Th1 cytokines indicated significantly higher Th1/proinflammatory cytokine production in PE as compared to normal pregnancies [122]. Flow cytometric measurement of intracellular cytokines demonstrated a shift towards predominantly Th1-type reactivity in PE [119]. The increased levels of activated T cells [123] and the tilt towards Th1 dominance in PE suggests important roles for T cells in the pathogenesis of PE. There appears to be a clear increase in Th1 versus Th2 reactivity in women with PE [42, 124], and this has been shown to be initiated before the clinical manifestation of PE, suggesting a cause-and-effect relationship [109].

Zenclussen [125] described a mouse model of PE in which the adoptive transfer of Th1-like cells into pregnant mice provokes PE symptoms such as increased BP and glomerulonephritis accompanied by proteinuria, in addition to effecting an inflammatory profile among uterine immune cells. This study provides strong support for a role for Th1-type reactivity in PE [125].

What stimulates the production of proinflammatory cytokines in PE? Trophoblast microparticles may contribute to this in great part as these have been shown to stimulate the production of the proinflammatory cytokines TNF-α, IL-12, IL-18, IL-1β, IL-6, and IL-8 by monocytes [126] in PE. Cytokines may contribute to an increased release of trophoblast microparticles by stimulating enhanced trophoblast apoptosis, and subsequently these microparticles could cause elevated systemic production of proinflammatory cytokines, thus supporting the contention that cytokines play key roles in both stages of PE. In addition to Th1 and Th2 cells, T cells may also differentiate into the distinct lineages of Treg and Th17 cells. Treg cells play key roles in the regulation of inflammation, while Th17 cells secrete the proinflammatory cytokine IL-17 and mediate potent tissue inflammation. The numbers of a subset of regulatory T cells with immunosuppressive capabilities, i.e. Treg cells, are significantly lower in PE compared to normal pregnancies [127], while Th17 cells are increased [111]. The increase in proinflammatory Th17 cells and the decrease in the immunosuppressive Treg cells is proposed to contribute to the pathophysiology of PE [128] via the induction of unbridled inflammation and endothelial dysfunction [11]. However, the laboratory of Zenclussen demonstrated that the levels of Treg cells were similar in PE and normal pregnancy, questioning the role of Treg cells in averting PE [129].

**Mechanisms of Action of Cytokines in PE**

The pathophysiologic mechanisms underlying the initial placental changes and subsequent development of endothelial dysfunction, hypertension, proteinuria, and edema in PE have been the subject of intense investigation over the years, and these aspects are now much better understood. PE is basically a condition of generalized endothelial cell dysfunction [12, 23]; the disturbed endothelium results in the well-known classical features of PE—the hypertension is attributable to vasoconstriction, the proteinuria is attributable to glomerular endotheliosis, and the edema is attributable to increased vascular permeability [47].

Generalized activation or injury of maternal vascular endothelial cells leading to microthrombus formation and vasospasm [130] is an important observation in PE. Given the powerful effects of cytokines on endothelial cells (table 1), the increased tendency for maternal blood cells to produce inflammatory cytokines in PE is significant. Maternal proinflammatory cytokines are likely to be the most important effectors of these effects [42, 100, 101,
increased endothelial cell permeability, and vascular cell adhesion molecule-1, in-
IL-1 cause increased production of thrombin, platelet-ac-
constrictive endothelial cells, and production of antian-
coagulation, and thus instigate inflammatory responses
[137–139], TNF-α has been shown to induce the activa-
tion of endothelial cells and to cause endothelial damage
[75]. Increased concentrations of IL-8 are associated with

Table 1. Inflammatory cytokines and endothelial dysfunction

| Cytokine | Effect |
|----------|--------|
| TNF-α    | Activates endothelial cells |
|          | Increases coagulation |
|          | Increases the expression of adhesion molecules |
|          | Increases vascular permeability |
|          | Induces microvascular leakage |
| IL-1     | Increases thrombin production and coagulation |
|          | Induces the production of platelet-activating factor |
|          | Stimulates the expression of adhesion molecules |
| IL-6     | Increases vascular permeability |
| IL-8     | Activates endothelial cells |

107, 109, 113, 122]. In fact, Redman et al. [131] affirmed that the clinical features of PE are best described as an ex-
cessive maternal inflammatory response mediated by cy-
tokines, and that cytokine action is one of the most attrac-
tive hypotheses of immunological dysfunction in this
syndrome.

At the level of the placenta, the cytokines IL-6 and
TNF-α were shown to induce excessive or abnormal
apoptotic and necrotic death of trophoblast cells; these
cells were shown to induce endothelial activation when
shed [132]. Thus cytokines appear to be involved in the
early (i.e. stage 1) events of PE. The pattern of increased
placental and systemic cytokines appears to be consistent
with increased systemic inflammatory activation, the re-
lease of vasoconstrictory factors, endothelial dysfunction,
and hypertension, which are all part of the syndrome of
PE [133]. The widespread maternal vascular endothelial
dysfunction is suggested to be caused by proinflamma-	ory cytokines [66] and, along with other mediators such
as endothelin and thromboxane, are proposed to contrib-
tute to hypertension, proteinuria, and edema [130]. Benyo
et al. [83] pointed out that proinflammatory cytokines are
‘notorious’ for effecting changes in the endothelium in the
same manner as that seen in PE. TNF-α has potent
effects on endothelial and platelet function, it enhances
cogulation, microvascular leakage, activation of vaso-
constrictive endothelial cells, and production of antian-
giogenesis factors like tissue factor [134, 135]. TNF-α and
IL-1 cause increased production of thrombin, platelet-ac-
tivating factor, and vascular cell adhesion molecule-1, in-
creased endothelial cell permeability [136], and enhanced
cogulation, and thus instigate inflammatory responses
[137–139], TNF-α has been shown to induce the activa-
tion of endothelial cells and to cause endothelial damage
[75]. Increased concentrations of IL-8 are associated with
increased activation of neutrophils [140], while IL-6 is
known to activate endothelial cells [89], to induce in-
creased permeability of endothelial cells, and to bring
about systemic effects that resemble the inflammatory
acute phase response.

It may be pertinent to refer to another factor that ap-
ppears to be involved in the pathogenesis of PE. Zenclussen
et al. [141] showed that the expression of the heme-de-
grading enzymes heme oxygenases (HO)-1 and HO-2 is
reduced in PE. They suggested that low expression of
HO-2 may lead to enhanced levels of free heme at the
feto-maternal interface, followed by upregulation of ad-
hesion molecules which would then encourage the migra-
tion of inflammatory cells to the feto-maternal interface;
this points to the involvement of HO in PE [142]. HO-1 plays
an important role in placental vasculature development,
and a deficiency in HO-1 may contribute to preg-
nancy complications, such as PE. The unique combina-
tion of tissue-protective, smooth-muscle-relaxing, and
angiogenesis-regulatory properties makes HO-1 a key
player in the maintenance of a healthy pregnancy through
a direct effect on placental structural and vascular devel-
oment [143].

A fascinating nexus between cytokines and BP control
is now being unraveled. Hayashi et al. [144] reported a
positive correlation between increased production of the
inflammatory cytokines IL-2, IFN-γ, and TNF-α by pe-
ipheral blood leukocytes in PE and mean BP. Chronic
infusions of IL-6 or TNF-α into normal pregnant rats in-
crease arterial pressure and affect renal hemodynamics
[41]. A recent study on pregnant baboons showed that the
infusion of TNF-α is followed by an increase in systolic
diastolic BP and proteinuria, indicating that TNF-α
can induce the clinical and biochemical features of hu-
man PE and also showing a clear association of TNF-α
with endothelial dysfunction and BP control [145].
TNF-α activates the endothelin system in placental, vas-
cular, and renal tissues, while IL-6 activates the renin-
angiotensin system [41]. Proinflammatory cytokines pro-
duced in PE may contribute to hypertension by inducing
the production of vascular mediators that result in vaso-
constriction and consequently hypertension [146]. Cyto-
kines are suggested to be linked to hypertension by pro-
voking inflammation, which would result in vascular in-
jury and may also contribute to elevated BP by causing
kidney injury [147]. In a rat model of PE, Tinsley et al.
[148] showed that the Th1-like cytokines IL-2, IL-12, and
IFN-γ were elevated; immunosuppression with azathiop-
rine or mycophenolate not only resulted in a significant
reduction of Th1 cytokines but also decreased the associ-
ated hypertension, proteinuria, and endothelial dysfunction (table 2).

Increased Th1 reactivity [42, 122] and Th17 levels [149] in PE may induce exaggerated systemic inflammation and vascular endothelial dysfunction. That TNF-α may contribute directly to proteinuria is supported by a recent study on diabetic nephropathy in which a positive correlation was observed between plasma TNF-α levels and urinary protein concentrations [150].

**Immunomodulation for Therapeutic Intervention in PE?**

The possibility of rational development of immunomodulatory approaches for the treatment of PE is supported by research on anti-inflammatory cytokines like IL-10 and on the suppression of proinflammatory cytokines.

A negative correlation has been reported between BP and serum levels of IL-10 [94], and this has also been demonstrated experimentally in nonhuman primates [151]. A recent elegant study by Chatterjee et al. [152] showed that TLR3 activation during murine pregnancy induced an increase in systolic BP and endothelial function, demonstrating a connection between immune activation and symptoms of PE. TLR3 activation was shown to be associated with a proinflammatory state along with an increase in proinflammatory cytokines. Interestingly, a deficiency in IL-10 along with TLR3 activation brings about an exacerbation of PE symptoms; the addition of recombinant IL-10 prevented these symptoms, demonstrating the importance of IL-10 in this equation. These observations are significant given the well-documented anti-inflammatory properties of IL-10 and the demonstration that IL-10 deficiency is associated with PE-like symptoms. In pregnant baboons, the administration of anti-IL-10 antibody results in a significant increase in mean arterial pressure via regulation of vasodilation [151]. Chatterjee et al. [152] proposed that recombinant IL-10 may be considered for use in preventing PE. More evidence of the important role of IL-10 comes from observations that IL-10 knockout mice have mild hypertension, endothelial dysfunction, and inflammation [153].

The possibility of manipulating cytokine production for therapeutic intervention in PE is supported by the recent study of Keiser et al. [154]. This study on pregnant rats showed that progesterone inhibits TNF-α-stimulated production of endothelin-1 by endothelial cells and suggested that such immunomodulatory approaches may be considered for PE. This study and the experiments on infusion of IL-10 offer a scope for optimism that better understanding of the pathogenesis of this rather mysterious disorder will lead to the rational development of treatments. Our work demonstrating the effects of the orally administered progesterone derivative dydrogesterone (6-dehydro-9β, 10α-progesterone) is pertinent. Dydrogesterone (Duphaston®) is a potent orally administered progestogen, similar to endogenous progesterone in its molecular structure and pharmacological effects, with a high affinity for the progesterone receptor. We have shown that dydrogesterone brings about a significantly reduced secretion of the Th1 cytokines IFN-γ and TNF-α and a significant increase in the levels of the Th2 cytokines IL-4 and IL-6 [155, 156]. In view of the fact that the relative levels of Th1 and Th2 cytokines are probably of greater importance than their absolute levels alone, we calculated the ratios of Th1 to Th2 cytokines and found a marked reduction in the Th1/Th2 ratios (e.g. IFN-γ/IL-4, IFN-γ/IL-10) in PBMC cultures containing dydrogesterone. Thus, dydrogesterone redirects Th1/Th2 profiles in lymphocytes from women with recurrent miscarriage [155] and preterm delivery [156] by downregulating the production of proinflammatory cytokines and upregulating the production of anti-inflammatory cytokines [157]. This could well result in a substantial swing in Th1/Th2 reactivity towards the pregnancy-conducive Th2 profile and away from the potentially harmful Th1 profile. In fact, dydrogesterone downregulates the very cytokines, i.e. TNF-α and IFN-γ, that are implicated in many of the manifestations of PE. Redman et al. [131] suggested that the clinical features of PE are best described as an excess-

| **Table 2. Cytokines and hypertension** |
|----------------------------------------|
| Infusion of TNF-α or IL-6 into pregnant rats increases arterial BP. |
| Infusion of TNF-α into pregnant baboons causes increases in BP and proteinuria. |
| TNF-α activates the endothelin system in the kidneys. |
| IL-6 activates the renin-angiotensin system. |
| Proinflammatory cytokines cause vasoconstriction. |
| Suppression of proinflammatory cytokines results in reduction of hypertension and proteinuria. |
| There is a negative correlation between IL-10 levels and BP. |
| Infusion of IL-10 leads to improvement of PE-like symptoms in mice. |

Cytokines and PE
sive maternal inflammatory response, mediated by cytokines. If indeed a Th1 predominance is responsible for PE and if Th2 bias is associated with a successful pregnancy, then immunomodulatory agents like dydrogesterone may be worth considering for use in PE. It is tempting to speculate that modulation of cytokine profiles by therapeutic supplementation with progestogens like dydrogesterone may be an attractive treatment option for PE.

**Conclusion**

Sufficient evidence from animal and human studies has now been gathered to reveal the pathogenesis of PE on the basis of the influence of cytokines both in the placenta and in the periphery. A unifying hypothesis for PE is that inadequate trophoblast invasion and remodeling of spiral arteries stimulate placental ischemia and hypoxia via intermittent perfusion of the placenta; this results in an increased release of trophoblast microparticles into the maternal circulation followed by increased production of maternal proinflammatory cytokines and activation of maternal endothelial cells. This is proposed to eventually lead to ‘systemic, diffuse endothelial cell dysfunction’, the fundamental pathophysiological feature of this syndrome.

While understanding the etiology and pathophysiology of PE is certainly of interest from a basic medical science perspective, it also has important implications for the treatment and management of this dangerous complication. There is renewed optimism that basic and clinical research which has helped elucidate the pathogenesis of this disease will lead to the rational design of interventions for the management and treatment of this important and common complication of pregnancy.

**Acknowledgements**

This work was supported by Kuwait University Research Administration grant MI 02/10.

**Disclosure Statement**

The author declares no conflict of interest.

### References

1. Sibai BM: Hypertensive Disorders in Women. Philadelphia, Saunders, 2004.
2. American College of Obstetricians and Gynecologists: Diagnosis and management of pre-eclampsia and eclampsia — ACOG practice bulletin No 22. Obstet Gynecol 2002;99:159–167.
3. National Heart Lung and Blood Institute: Report of the Working Group on Research on Hypertension during Pregnancy. 2000. http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_preg.htm (accessed June 10, 2010).
4. Barron WM: Hypertension; in Barron WM, Lindheimer MD (eds): Medical Disorders of Pregnancy. St. Louis, Mosby Year Book, 1991, pp 1–41.
5. Chang J, Elam-Evans LD, Berg CJ: Pregnancy-related mortality surveillance: United States 1991–1998. MMWR Surveill Summ 2003;52:1–8.
6. Leeman L, Fontaine P: Hypertensive disorders of pregnancy. Am Fam Physician 2008; 78:93–100.
7. Redman CW, Walker I: Preeclampsia: The Facts – The Hidden Threat to Pregnancy. Oxford, Oxford University Press, 1992.
8. Zweifel P: Eklampsie; in Döderlein A (ed): Handbuch der Geburtshilfe. Wiesbaden, Bergmann, 1916, pp 672–723.
9. Maharaj B, Moodley J: Management of hypertension in pregnancy. Conti Med Educ 1994; 12:1581–1589.
10. Lain KY, Roberts JM: Contemporary concepts of the pathogenesis and management of preeclampsia. J Am Med Assoc 2002;287:3183–3186.
11. Saito S: Th17 cells and regulatory T cells: new light on pathophysiology of preeclampsia. Immunol Cell Biol 2010;88:615–617.
12. Sargent IL, Borzychowski AM, Redman CW: Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online 2006;13:680–686.
13. Pijnenborg R, Robertson WB, Brosens I, et al: Trophoblast invasion and the establishment of haemochorial placentation in man and laboratory animals. Placenta 1981;2:71–91.
14. Robertson WB, Brosens I, Pijnenborg R, et al: The making of the placental bed. Eur J Obstet Gynecol Reprod Biol 1984;18:255–266.
15. Gerretsen G, Huisjes HJ, Hardonk MJ, et al: Trophoblast alterations in the placental bed in relation to physiological changes in spiral arteries. Br J Obstet Gynaecol 1983;90:34–39.
16. Eastabrook G, Brown M, Sargent I: The origin and end-organ consequence of pre-eclampsia. Best Pract Res Clini Obstet Gynaecol 2011; 25:435–447.
17. Genbacev O, Joslin R, Damsky CH, et al: Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Invest 1996;97:540–550.
18. Zhou Y, Genbacev O, Damsky CH, et al: Oxygen regulates human cytotrophoblast differentiation and invasion: implications for the endovascular invasion in normal pregnancy and in pre-eclampsia. J Reprod Immunol 1998;39:197–213.
19. Kingdom JC, Kaufmann P: Oxygen and placental vascular development. Adv Exp Med 1999;474:259–275.
20. Roberts JM, Gamill HS: Preeclampsia: recent insights. Hypertension 2005;46:1243–1249.
21. De Wolf F, Robertson WB, Brosens I: The ultrastructure of acute atherosis in hypertensive pregnancy. Am J Obstet Gynecol 1975;123:164–174.
22. Kovo M, Schreiber L, Ben-Haroush A, et al: Placental vascular lesion differences in pregnancy-induced hypertension and normotensive fetal growth restriction. Am J Obstet Gynecol 2010;202:561.e1–561.e5.
23. Redman CW, Sargent IL: Latest advances in understanding preeclampsia. Science 2005; 308:1592–1594.
77 Conrad JP, Benyo DF: Placental cytokines and the pathogenesis of preeclampsia. Am J Obstet Gynecol 1999;181:913–920.

78 Crocker IP, Cooper S, Ong SC, et al: Differенces in apoptotic susceptibility of cytotrophoblasts with and without vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004;95:884–891.

79 Gilbert JS, Ryan MJ, LaMarca BB, et al: Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008;294:H541–H550.

80 Huang SJ, Zenclussen AC, Chen CP et al: The implication of aberrant GM-CSF expression in decidua cells in the pathogenesis of preeclampsia. Am J Pathol 2010;177:2472–2482.

81 Vincent GS, Starkley PM, Austgulen R, et al: Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995;102:20–25.

82 Conrad KP, Miles TM, Benyo DF: Circulating levels of immunoreactive cytokines in women with preeclampsia. J Reprod Immunol 1998;40:102–111.

83 Serin IS, Ozelik B, Basbug M, et al: Predictive value of tumor necrosis factor alpha (TNF-alpha) in preeclampsia. Eur J Obstet Gynecol Biol 2002;100:143–145.

84 Velzing-Aarts FV, Muskiet FA, van der Dijs FP: High serum interleukin-8 levels in Afro-Caribbean women with preeclampsia: relationships with tumor necrosis factor-alpha, duffy negative phenotype and von Willebrand factor. Am J Obstet Gynecol 2002;188:319–322.

85 Tsuchihashi S, Sargent IL, et al: Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998;179:80–86.

86 Chen G, Wilson R, Wang SH, et al: Tumor necrosis factor-a (TNF-a) gene polymorphism and expression in preeclampsia. Clin Exp Immunol 1996;104:154–159.

87 Raghupathy

88 Kupferminc MJ, Peaceman AM, Aderka D, et al: Soluble tumor necrosis factor receptors in maternal plasma and second trimester amniotic fluid. Am J Obstet Gynecol 1995;173:900–905.

89 Sibai B, Romero R, Klebanoff MA: Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia. Am J Obstet Gynecol 2009;200:630.e1–e8.

90 Hamay, Fujii T, Yamashita T, et al: Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical manifestations of pre-eclampsia. Am J Reprod Immunol 1997;38:89–93.

91 Jonsson Y, Ruber M, Matthiesen L, et al: Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J Reprod Immunol 2006;70:83–91.

92 Freeman DJ, McManus FM, Brown EA: Short- and long-term changes in plasma inflammatory markers associated with pre-eclampsia. Hypertension 2004;44:708–714.

93 Nakabayashi M, Sakura M, Takeda Y, et al: Elevated IL-6 mid-trimester amniotic fluid is involved with the onset of preeclampsia. Am J Reprod Immunol 1998;39:329–334.
Szaraka A, Rigo Jr, Lazar L, et al: Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010;11:59–64.

Omu AE, Al-Qattan F, Diejomah ME: Differential levels of T helper cytokines in pre-eclampsia: pregnancy, labor and puerperium. Acta Obstet Gynecol Scand 1999;78:675–680.

Saito S, Umekage Y, Sakamoto M, et al: Increased T helper-1-type immunity and decreased T helper-2-type immunity in patients with preeclampsia. Am J Reprod Immunol 1999;41:297–306.

Darmochwal-Kolarz D, Rolinski J, Leszczynska-Goarzelak B: The expressions of intracellular cytokines in the lymphocytes of preeclamptic patients. Am J Reprod Immunol 2002;48:381–386.

Germain SJ, Schondorf T, Gohring UJ: Cytokines and PE. Med Princ Pract 2013;22(suppl 1):8–19.

Foxp3+ and IL-17-producing CD4+ T cells in normal pregnancy and preeclampsia. J Immunol 2009;183:7023–7030.

Sibai BM: Initiators of severe pre-eclampsia: Semin Perinatol 2009;33:196–205.

Redman CW, Sacks GP, Sargent IL: Pre-eclampsia: an excessive maternal response to pregnancy. Am J Obstet Gynecol 1999;180:499–506.

Sibai BM: Initiators of severe pre-eclampsia. Semin Perinatol 2009;33:196–205.

George EM, Granger JP: Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens 2011;24:964–969.

Leibowitz A, Schiffrin EL: Immune mechanisms in hypertension. Curr Hypertens Rep 2011;13:465–472.

Saito S, Nakashima A, Shima T, et al: Th1, Th2, Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 2010;63:601–610.

Taslinski P, Chiasson VL, South S, et al: Immunosuppression improves blood pressure and endothelial function in a rat model of pregnancy-induced hypertension. Am J Hypertens 2009;22:1107–1114.

Saito S, Nakashima A, Shima T, et al: Intraperitoneal injection of TNF-alpha with TGFbeta promote nonapoptotic trophoblast degradation and subsequently causes endothelial cell activation. Placenta 2010;31:75–80.

Kharfi A, Giguere Y, Sapin V, et al: Thrombolytic remodeling in normal and preeclamptic pregnancies: implication of cytokines. Clin Biochem 2003;36:322–331.

Koller S, Nickel T, Weis M: Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond) 2005;108:205–213.

Naldini A, Carraro F: Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 2005;4:3–8.

Kaplansjuki G, Fabrigoule M, Boulay V: Heme oxygenases in pregnancy II: HO-2 is downregulated in human pathologic pregnancy. Semin Perinatol 2009;33:196–205.

Tinsley JH, Chiasson VL, South S, et al: Immunosuppression improves blood pressure and endothelial function in pregnant women with recurrent miscarriage. Br J Obstet Gynaecol 2011;118:268–275.

Orange S, Horvath J, Hennessy A: Increased pro-inflammatory cytokines in the lymphocytes of normal pregnancy and preeclampsia: the role of cytokine imbalance in pregnancy complications and its relationship with diastolic blood pressure and fibronectin levels. Acta Obstet Gynecol Scand 2003;82:797–802.

Granger JP, Alexander BT, Llinas T, et al: Analysis of superoxide generation, cytokine production, and adhesion molecular production in normal pregnant and preeclamptic patients. J Soc Gynecol Investig 1997;4:912A.

Szekanecz Z, Kato H, Nishimura Y, et al: Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and preeclampsia. Eur J Haematol 2002;69:297–302.

Zenclussen AC, Lim E, Knoeller S, et al: Heme oxygenases in pregnancy II: HO-2 is downregulated in human pathologic pregnancies. Am J Reprod Immunol 2003;50:66–76.

Wong RJ, Zhao H, Stevenson DK: A deficiency in haem oxygenase-1 induces foetal growth restriction by placental vasculature defects. Acta Paediatr 2012;101:827–834.

Zhao H, Wong RJ, Kalish FS, et al: Effect of heme oxygenase-1 deficiency on placental development. Placenta 2009;30:861–868.

Hayashi M, Inoue T, Hoshimoto K, et al: Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and preeclampsia. Am J Reprod Immunol 2005;54:30–37.

Sakaki Y, Darmochwal-Kolarz D, Suzuki D, et al: Proportion of peripheral blood and decidual CD4+ CD25(bright) regulatory T cells in pre-eclampsia. Clin Exp Immunol 2007;149:139–145.

Santner-Nanan B, Peek MJ, Khanam R, et al: Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol 2009;183:7023–7030.

Claman JY, Rapaport V, Repinski C, et al: Analysis of superoxide generation, cytokine production, and adhesion molecular production in normal pregnant and preeclamptic patients. J Soc Gynecol Investig 1997;4:912A.

Heinegard D, Alm P, Ohlsson A, et al: Identification of circulating syncytiotrophoblast microparticles. J Immunol 2007;178:5949–5956.

Sakaki Y, Darmochwal-Kolarz D, Suzuki D, et al: Proportion of peripheral blood and decidual CD4+ CD25(bright) regulatory T cells in pre-eclampsia. Clin Exp Immunol 2007;149:139–145.